COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler

Arslan, Fatma Demet; Karakoyun, İnanç

COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler

Fatma Demet ARSLAN, (Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya, İzmir, Türkiye)

İnanç KARAKOYUN (Sağlık Bilimleri Üniversitesi, Tepecik Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya, İzmir, Türkiye)

Türk Klinik Biyokimya Dergisi

2 1

Yıl: 2021 Cilt: 19 Sayı: 2 Sayfa Aralığı: 165 - 176 Metin Dili: Türkçe İndeks Tarihi: 18-11-2022

COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler

Öz:

COVID-19 pandemisi ile birlikte laboratuvar tıbbının önemi bir kez daha gündeme gelmiş ve laboratuvar işleyişi açısından çok önemli değişiklikler gerçekleşmiştir. Çalışan sağlığı ile ilgili önlemler, personel görevlendirilmesi ile ilgili planlamalar, test çeşitliliği ve sayısındaki değişimler, kalite standartlarındaki yenilikler ve laboratuvarların bilimsel çalışmalara olan katkısı bunlardan bazılarıdır. Çalışan sağlığı ve iş yükü dağılımındaki değişimler nedeniyle bazı tedbirler alınmış ve afet planları güncellenmiştir. Tüm sağlık çalışanları biyolojik tehdit ile karşı karşıya geldiğinde global bir çaba ortaya çıkmıştır. Laboratuvarlar arası iş birliği ve multidisipliner yaklaşım bu çabaya katkıda bulunmuştur. Bu derleme, COVID-19 pandemisinde yerel, ulusal ve uluslararası düzeyde yaşanan laboratuvar süreçlerini özetlemektedir.

Anahtar Kelime:

Processes Experienced in Laboratories during COVID-19 Pandemic

Öz:

The importance of laboratory medicine during CO VID-19 pandemic has once again become a current issue. With COVID-19 pandemic, very important changes have occurred in terms of laboratory processing. Some of these changes were measures related to employee health, planning regarding the assignment of personnel, changes on the variety and nu mber of tests, innovations in quality standards and the contribution of laboratories to scientific studies. Due to change s in employee health and workload distribution, some precautions were taken and disaster plans were updated. A global effort has spent when all healthcare prof essionals come up against the bi ological threat. Interlaboratory collaboration and a multidisciplinar y approach have contributed to this effort. This review has been summarized the experienced laboratory processes at local, national and inte rnational levels during COVID-19 pandemic.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Williams TL, Potenza G, Paz Carlos M, Mangal CN, Rank EL, Sambol AR, et al. GP36-A Planning for Laboratory Operations During a Disaster; Approved Guideline. 2014; 34(19).
2. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID19) and other viral outbreaks. Clin Chem and Lab Med 2020; 58(7):1063-1069.
3. Lippi G, Plebani M. Laboratory medicine resilience during coronavirus disease 2019 (Covid-19) pandemic. Adv Lab Med 2020; 20200035.
4. Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. JAMA 2020; 323(15), 1439-1440.
5. Sharma B, Shahanshah MF, Gupta S, Gupta V. Recent advances in the diagnosis of COVID-19: A bird's eye view. Expert Rev Mol Diagn 2021; 21(5): 475-491.
6. Ren X, Liu Y, Chen H, Liu W, Guo Z, Zhang Y, et al. Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection. medRxiv 2020.
7. Lippi G. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed 2020; 91(2):137-145.
8. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID19 detection: issues affecting the results. Expert Rev Mol Diagn 2020;20(5):453-454.
9. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory diagnosis of COVID-19: Current issues and challenges. J Clin Microbiol 2020;58(6): e00512-20.
10. Phan T. Genetic diversity and evolution of SARSCoV-2. Infect Genet Evol 2020;81: 104260.
11. Shen Z, Xiao Y, Kang L, Ma W, Shi L, Zhang L, et al. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients. Clin Infect Dis 2020: ciaa203.
12. https://www.cdc.gov/corona virus/2019-ncov/lab/rtpcr-detection-instructions.html.
13. Merindol N, Pépin G, Marchand C, Rheault M, Peterson C, Poirier A, et al. SARS-CoV-2 detection by direct rRT-PCR without RNA extraction. J ClinVirol 2020; 128, 104423.
14. Grant PR, Turner MA, Shin GY, Nastouli E, Levett LJ. Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic. BioRxiv 2020.
15. Mokhtar KM. Improved COVID-19 testing by extraction-free SARS-CoV-2 RT-PCR. EJIFCC 2020; 31(4), 362-368.
16. Guo L, Ren L, Yang S, Xiao M, Chang, D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020; 71(15):778-785.
17. Padoan A, Cosma C, Sciacovelli L, Faggian, D, Plebani M. Analytical performances of a chemiluminescence immunoassay for 2019-nCov IgM/ IgG and antibody kinetics. Clin Chem Lab Med 2020; 58(7): 1081-1088.
18. Lippi G, Salvagno GL, Pegoraro M, Militello V, Caloi C, Peretti A, et al. Assessment of immune response to SARS-CoV-2 with fully-automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med 2020; 58(7):1156-1159.
19. Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis 2020; 94: 49-52. Arslan D.F. ve Karakoyun İ. 176 Türk Klinik Biyokimya Derg 2021;19(2)
20. Du Z, Zhu F, Guo F, Militello V, Caloi C, Peretti A, et al. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J Med Virol 2020; 58(7):1156-1159.
21. Pan Y, Li X, Yang G, Fan J, Tang, Y, Zhao J, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infec 2020; 81(1): e28-e32.
22. https://www.centerforhealthsecurity.org/resources/C OVID-19/serology/Serology-based-tests-for-COVID19.html.
23. World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19): interim guidance, 13 May 2020 (No. WHO/WPE/ GIH/2020.3). Geneva: World Health Organization; 2020.
24. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382(16), 1564-1567.
25. World Health Organization Staff, World Health Organization. Laboratory biosafety manual: third edition. Geneva: World Health Organization; 2004.
26. CDC 2019-Novel Coronavirus (2019-nCoV) RealTime RT-PCR Diagnostic Panel. Atlanta: Centers for Disease Control and Prevention; 2020.
27. World Health Organization. Guidance on regulations for the transport of infectious substances 2019– 2020: applicable from 1 January 2019 (No. WHO/WHE/CPI/2019.20). Geneva: World Health Organization; 2019.
28. Chin A, Chu J, Perera M, Hui K, Yen HL, Chan M, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020; 1(1):e10.
29. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect 2020; 104(3):246-251.
30. World Health Organization. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance, 19 March 2020 (No. WHO/2019-nCoV/IPC PPE_use/2020.2). Geneva: World Health Organization; 2020.
31. World Health Organization. Rational use of personal protective equipment for COVID-19 and considerations during severe shortages: interim guidance, 23 December 2020 (No. WHO/2019- nCov/IPCPPE_use/2020.4. Geneva: World Health Organization; 2020.
32. COVID-19 (SARS-CoV-2 Enfeksiyonu) Laboratuvar Biyogüvenlik Rehberi, Sağlık Bakanlığı, Sağlık Hizmetleri Genel Müdürlüğü Tetkik ve Teşhis Hizmetleri Daire Başkanlığı, Tıbbi Laboratuvarlar Bilim Komisyonu, 8 Nisan 2020.
33. World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance, 29 June 2020 (No. WHO/2019-nCoV/IPC/ 2020.4). Geneva: World Health Organization; 2020.
34. COVID-19 Pandemisinde Atık Yönetimi, Sağlık Bakanlığı, 13 Nisan 2020.
35. Gündoğmuş N, Güler S. COVID-19 ve Temel Bilimler. Yiyit N, Bakan N, Güven Ş, Uğur M, Demir S, Temiz SG, editör. COVID-19 ve Pandemi Hastanesine Dönüşüm. 1.Baskı, İstanbul: Nobel Tıp Kitapevi; 2020. p. 33-42.
36. CLSI. Training and competence assessment, 4th ed. CLSI guideline QMS03. Wayne, PA: Clinical and Laboratory Standards Institute, 2016.
37. Loh TP, Horvath AR, Wang CB, Koch D, Adeli K, Mancini N, et al. Operational considerations and challenges of biochemistry laboratories during the COVID-19 outbreak: an IFCC global survey. Clinical Chemistry and Laboratory Medicine (CCLM) 2020; 58(9): 1441-1449.
38. Jafri L, Ahmed S, Siddiqui I. Impact of COVID-19 on laboratory professionals-A descriptive cross sectional survey at a clinical chemistry laboratory in a developing country. Ann Med Surg (Lond) 2020; 57: 70-75.
39. Thompson S, Bohn MK, Mancini N, Loh TP, Wang CB, Grimmler M, et al. IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients. Clinical Chemistry and Laboratory Medicine (CCLM) 2020; 58(12), 2009-2016.
40. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med 2020; 383: 347-358.
41. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clinica Chimica Acta 2020; 505: 190- 191.
42. Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. Journal of Medical Virology 2021; 93(1), 35-37.
43. Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta 2020; 507: 161-3.
44. Ahmed S, Jafri L, Majid H, Khan AH, Ghani F, Siddiqui I. Challenges amid COVID-19 times - Review of the changing practices in a clinical chemistry laboratory from a developing country. Ann Med Surg (Lond) 2020;55:300-304.
45. Gazete TR. Biyolojik Etkenlere Maruziyet Risklerinin Önlenmesi Hakkında Yönetmelik. Resmi Gazete Sayısı, 28678.

APA	Arslan F, Karakoyun İ (2021). COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. , 165 - 176.
Chicago	Arslan Fatma Demet,Karakoyun İnanç COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. (2021): 165 - 176.
MLA	Arslan Fatma Demet,Karakoyun İnanç COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. , 2021, ss.165 - 176.
AMA	Arslan F,Karakoyun İ COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. . 2021; 165 - 176.
Vancouver	Arslan F,Karakoyun İ COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. . 2021; 165 - 176.
IEEE	Arslan F,Karakoyun İ "COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler." , ss.165 - 176, 2021.
ISNAD	Arslan, Fatma Demet - Karakoyun, İnanç. "COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler". (2021), 165-176.

APA	Arslan F, Karakoyun İ (2021). COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. Türk Klinik Biyokimya Dergisi, 19(2), 165 - 176.
Chicago	Arslan Fatma Demet,Karakoyun İnanç COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. Türk Klinik Biyokimya Dergisi 19, no.2 (2021): 165 - 176.
MLA	Arslan Fatma Demet,Karakoyun İnanç COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. Türk Klinik Biyokimya Dergisi, vol.19, no.2, 2021, ss.165 - 176.
AMA	Arslan F,Karakoyun İ COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. Türk Klinik Biyokimya Dergisi. 2021; 19(2): 165 - 176.
Vancouver	Arslan F,Karakoyun İ COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler. Türk Klinik Biyokimya Dergisi. 2021; 19(2): 165 - 176.
IEEE	Arslan F,Karakoyun İ "COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler." Türk Klinik Biyokimya Dergisi, 19, ss.165 - 176, 2021.
ISNAD	Arslan, Fatma Demet - Karakoyun, İnanç. "COVID-19 Pandemisinde Laboratuvarlarda Yaşanan Süreçler". Türk Klinik Biyokimya Dergisi 19/2 (2021), 165-176.